Newron Pharmaceuticals SPA
22
1
1
16
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
18.2%
4 terminated/withdrawn out of 22 trials
80.0%
-6.5% vs industry average
45%
10 trials in Phase 3/4
13%
2 of 16 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (22)
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
Role: lead
Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms
Role: lead
Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia
Role: lead
An Open Label, Single-Dose Study of 14C-NW-3509 in Healthy Male Subjects
Role: lead
A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging
Role: lead
Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients
Role: lead
Efficacy and Safety of Ralfinamide in Patients With Chronic Neuropathic Low Back Pain
Role: lead
A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.
Role: lead
A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia
Role: lead
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
Role: lead
Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects
Role: lead
MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)
Role: lead
Safinamide Renal Impairment Trial
Role: lead
A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics
Role: lead
A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics
Role: lead
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
Role: lead
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
Role: lead
18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD
Role: lead
Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease
Role: lead
Phase II Dose Titration Study in Patients With Neuropathic Pain
Role: lead